FDA: Safety Alert for Hydroxychloroquine; New Parkinson Disease Treatment

Inbox

x

MPR Daily Dose <editor@email.empr.com> Unsubscribe

2:52 AM (9 hours ago)

to me

If you are having trouble viewing this email, click here.

MUST READS FDA Issues Safety Alert Regarding Use of Hydroxychloroquine, Chloroquine for COVID-19 Remestemcel-L Looks Promising in COVID-19 Patients With Moderate to Severe ARDS Lopinavir/Ritonavir, Umifenovir Ineffective for Mild COVID-19 Ongentys Approved as Add-On Treatment for Parkinson Disease FDA Approves Quadrivalent Meningococcal Vaccine MenQuadfi COVID-19 Resource Center Featured Content Exploring Real-World Data Use Around the World Conducting real-world data analyses to generate real-world evidence is becoming increasingly common. What are the applications and limitations of this practice? Find Out Now. CME/CE Spotlight Patient-Centric Communication: Focus on IBS-C AMA PRA Category 1 Credit(s)TM, CE for Pharmacists CLICK HERE FOR A FULL LIST OF COURSES CE/CME Powered By myCME